Form 8-K · Current Report · Filed 2025-10-30
Alnylam Pharmaceuticals Reports Strong Q3 2025 Financial Results and Raises Guidance
Alnylam Pharmaceuticals, Inc. reported its third-quarter 2025 financial results on October 30, 2025, showing a significant increase in total net product revenues to $851 million, representing a 103% growth compared to Q3 2024. The company attributed this growth primarily to the robust performance of AMVUTTRA and ONPATTRO in the TTR franchise, alongside increased demand for GIVLAARI and OXLUMO in the Rare franchise. Alnylam also announced the initiation of two new Phase 3 trials and raised its full-year 2025 guidance for TTR franchise net revenues to $2.475 billion to $2.525 billion and total net product revenues to $2.95 billion to $3.05 billion. The company expects to initiate a Phase 2 trial of mivelsiran in Alzheimer's disease in the fourth quarter of 2025.
- Filer
- Alnylam Pharmaceuticals Inc. ALNY · NASDAQ
- Filed
- Accession
- 0001628280-25-047342
- CIK
- 0001178670
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$481.59
Next session
-5.3%
Since filing
-57.3%
Latest close
$205.52
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ALNY reporting the same item, with the next session's move:
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.
Never miss another ALNY filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.